





Those involved in type 2 diabetes caremust be puzzled by the lack of con-sensus on self-monitoring of blood
glucose (SMBG) (1,2,3), especially in
non–insulin-treated patients. This is re-
flected by wide between-country varia-
tion in reimbursement for glucose meters
and strips. Balanced evaluation of avail-
able data is required; however, further tri-
als are needed to provide robust evidence
as to how and in which groups SMBG use
is justified. Accordingly, diabetologists
and epidemiologists involved in recent
SMBG studies in type 2 diabetes met dur-
ing the 2006 International Diabetes Fed-
eration Congress and established an
International SMBG Working Group for
the exchange of data, analyses, and ideas.
Although there was no systematic invita-
tion strategy, 34 individuals from 13
countries have confirmed interest.
A cross-sectional Working Group
survey generated data from Argentina,
Australia, Canada, China, Germany, In-
dia, Italy, Netherlands, Norway, Pakistan,
Tanzania, the U.K, and the U.S. There are
no published data from one-half of these
countries, and none have national-level
data. For insulin-treated type 2 diabetic
patients, SMBG prevalence is highest in
countries providing free strips and is low-
est in countries like India where cost is a
major barrier. For patients taking oral an-
tidiabetes drugs, only Norway and the
U.K. provide free strips; however, in one-
half of the countries surveyed, most of
these patients use SMBG. The between-
country difference in frequency of strip
use is also marked.
Our data suggest that factors influ-
encing SMBG in type 2 diabetes include
country of residence, diabetes treatment,
and cost. The paucity of national-level
data are surprising given the high cost.
National guidelines unanimously recom-
mend SMBG in insulin-treated type 2 di-
abetes (1); however, there is lack of
consensus on the value of SMBG in non–
insulin-treated patients. This ad hoc sur-
vey has understandable gaps, and we
would like to invite others to contribute
and participate in future International
SMBG Working Group activities.
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APPENDIX
International SMBG Working Group
members who provided survey data
S. Bot, T.M.E. Davis, W.A. Davis, A.
Farmer, J.J. Gagliardino, C. Giorda, P.
Home, L. Ji, J. Johnson, A.J. Karter, H. Kolb,
S. Martin, V. Mohan, A. Nicolucci, M. Porta,
A. Ramachandran, K.L. Ramaiya, J.H. Shah,
A.S. Shera, and S. Skeie.
Other International SMBG Working
Group members
R. Bergenstal, E. Bosi, H.B. Chandalia, R.
Colagiuri, S. Colagiuri, M. Davidson, R.
Heine, L. Heinemann, L. Kennedy, D.
Owen, L.M.B. Laffel, and W.A. Scherbaum.
To contribute to and participate in fu-
ture International SMBG Working Group
activities, please contact H.K. through E-
mail: hubert.kolb@uni-duesseldorf.de.
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